Oral Administration of Starting Materials for In Vivo Synthesis of Antibacterial Gold Nanoparticles for Curing Remote Infections,Nano Letters

当前位置： X-MOL 学术 › Nano Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Oral Administration of Starting Materials for In Vivo Synthesis of Antibacterial Gold Nanoparticles for Curing Remote Infections
Nano Letters ( IF 9.6 ) Pub Date : 2021-01-16 , DOI: 10.1021/acs.nanolett.0c04578
Le Wang _{1,

2} , Junchuan Yang ₃ , Sixiang Li ₂ , Qizhen Li ₂ , Shaoqin Liu ₁ , Wenfu Zheng ₃ , Xingyu Jiang _{1,

2}

Affiliation

Oral administration is a facile and safe way for medication. However, most of the reported nanomedicines could not be taken orally, partially due to their unsatisfied stability, poor absorbance, or toxicity in the gastrointestinal tract. Here, we demonstrate that we could robustly synthesize gold nanoparticles (GNPs) in vivo by orally administering two starting materials, tetrachloroauric acid and aminophenyl boronic acid (ABA). The ABA-activated GNPs (A-GNPs) synthesized in vivo could be absorbed by the gastrointestinal tract and reach the remote infection lesions such as peritonitis caused by multidrug resistant (MDR) bacteria in mice. The A-GNPs exhibit excellent antibacterial efficacy (MIC, 3 μg/mL), long half-life (16–17 h), effective clearance (residual concentration is near 0 within 72 h), and high biosafety (safe dose/effective dose, 8 times). Our study is a pioneering attempt for synthesizing and taking nanomedicines orally just like preparing and drinking a cocktail.

中文翻译：

为起始原料的口服给药体内抗菌金纳米粒子合成的固化远程感染

口服给药是一种简便而安全的药物治疗方法。然而，大多数报告的纳米药物不能口服，部分是由于它们的稳定性不满意，吸收差或对胃肠道的毒性。在这里，我们证明了我们可以通过口服两种起始材料四氯金酸和氨基苯基硼酸（ABA）来稳健地体内合成金纳米颗粒（GNP ）。体内合成的ABA活化GNP（A-GNP）可以被胃肠道吸收并到达小鼠的多药抗性（MDR）细菌引起的远处感染病灶，例如腹膜炎。A-GNPs具有出色的抗菌功效（MIC，3μg/ mL），长半衰期（16-17小时），有效清除率（72小时内残留浓度接近0）和高生物安全性（安全剂量/有效剂量），8次）。我们的研究是口服合成和服用纳米药物的开创性尝试，就像制备和饮用鸡尾酒一样。

更新日期：2021-01-27

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11